An anti-COVID oral drug developed by the DRDO has been approved by the DCGI for emergency use as an adjunct therapy in moderate to severe coronavirus patients. Clinical trials of the drug 2-deoxy-D-glucose 2-DG showed that it helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. How it was developed, DRDO scientist Anant Narayan Bhatt told to Aajtak. Watch the full video.
Comments